Karlien Coene, theme Metabolic Disorders, together with the group of Jos Oomens and Jonathan Martens at the Radboud FELIX laboratory, published the discovery of novel biomarkers for pyridoxine-dependent epilepsy in the Journal of Clinical Investigation, based on the unique combination of untargeted metabolomics and infrared ion spectroscopy.
Pyridoxine-dependent epilepsy (PDE-ALDH7A1), also known as antiquitin deficiency, is an inborn error of lysine metabolism that presents with severe epilepsy in newborns. The biochemical result of this genetic condition is inactivation of vitamin B6, an important co-factor for many enzymatic processes in the human body. Vitamin B6 supplementation resolves epilepsy in patients, and additional lysine reduction therapy ensures optimal cognitive outcome, however, only when started in the first months of life. Ideally, early diagnosis through newborn screening would allow for pre-symptomatic detection of patients and early initiation of personalized treatment, however, so far no suitable blood-based biomarkers were available for this purpose.
By joining forces between the innovative analytical methods untargeted metabolomics and infrared ion spectroscopy, the research team was able to discover a novel biomarker for PDE-ALDH7A1, 2-oxopropylpiperidine-2-carboxylic acid, in short 2-OPP. This biomarker was shown to be compatible with newborn screening workflows. Additionally, it was shown that 2-OPP accumulates in brain tissue of patients and aldh7a1 knock-out mice, and induced epilepsy-like behavior in a zebrafish model system, which may indicate that 2-OPP itself contributes to ongoing neurotoxicity in PDE-ALDH7A1. As 2-OPP formation appears to increase upon ketosis, this knowledge translates directly into clinical practice, emphasizing the importance of avoiding catabolism in PDE-ALDH7A1 patients.
Related news items
Differences in the number of de novo mutations between individuals due to small family-specific effects and stochasticity28 July 2021
Christian Gilissen and colleagues investigated whether there is a family-specific contribution to the number of de novo mutations in the DNA of offspring and published the results in the Genome Research.read more
Christa Sperna Weiland, Erwin van Geenen and Joost Drenth discuss the best strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis28 July 2021
Christa Sperna Weiland, Erwin van Geenen and Joost Drenth, published in Lancet Gastroenterology & Hepatology a systematic review and network meta-analysis to determine the most efficacious prophylaxis strategy to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis.read more
ZonMw Gender in Research competition awarded to Genderful Research World Consortium27 July 2021
Natalia Valdrighi and Esmeralda Blaney Davidson won the competition to create a plan for the dissemination of the knowledge and skills gained during the Gender in Research workshop amongst their peers, colleagues and institution, financed by ZonMw and CIHR-IGH in Canada.read more
Young people with colorectal cancer deserve their own treatment27 July 2021
Richarda de Voer and Marjolijn Ligtenberg's study on clinical, pathological, genetic and molecular characteristics of colorectal tumors in adolescents and adults 25 years of age or younger is published in Clinical Gastroenterology and Hepatology.read more